Ahring et al, 2016
A pharmacological assessment of agonists and modulators at α4β2γ2 and α4β2d GABAA receptors: The challenge in comparing apples with oranges.
Pharmacological Research 111:563-576
Hartiadi et al, 2016
High and low GABA sensitivity α4β2d GABAA receptors are expressed in Xenopus laevis oocytes with divergent stoichiometries.
Biochemical Pharmacology 103:98-108
de Lucas et al, 2015
GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085.
Biochemical Pharmacology 93:370-379
Munro et al, 2009
Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets.
Trends in Pharmacological Sciences 30:453-459
Munro et al, 2008
Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain.
Journal of Pharmacology and Experimental Therapeutics 327:969-981
Ahring et al, 2015
Engineered α4β2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity α4-α4 interface.
Rasmussen et al, 2014
Biophysical and pharmacological characterization of α6-containing nicotinic acetylcholine receptors expressed in HEK293 cells.
Brain Research 1542:1-11
Grupe et al, 2013
Selective potentiation of (α4)3(β2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats.
Biochemical Pharmacology 86:1487-1496
Grupe et al, 2013
Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors.
British Journal of Pharmacology 168:2000-2010
Timmermann et al, 2012
Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.
British Journal of Pharmacology 167:164-182
Potassium Channel field
Nguyen et al, 2017
Potassium channel expression and function in microglia: plasticity and possible species variations.
Christophersen and Wulff, 2015
Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (Kca2.x and Kca3.1).
Grunnet et al, 2014
Kv7 channels as targets for anti-epileptic and psychiatric drug-development.
European Journal of Pharmacology 726:133-137
Dolga et al, 2014
Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons.
Cell Death and Disease 5:e999
Strøbæk et al, 2013
NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.
British Journal of Pharmacology 168:432-44